Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window of opportunity durvalumab trial in operable NSCLC (MIRACLE)
KCT0006973Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Mar 2022; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0006973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006973.